Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:54 AM
Ignite Modification Date:
2025-12-25 @ 2:54 AM
NCT ID:
NCT01420133
Eligibility Criteria:
Inclusion criteria :
* Age \> 18 years
* All patients for whom corticoids initially prescribed at a dose \> 20 mg per 24 hours, during a period of 3 months minimum
* Corticotherapy should be prescribed per os and continuously. (Alternating doses of corticoids, sequential intramuscular or intravenous injection of corticoids are not allowed in this clinical trial)
* All diseases requiring corticotherapy may be subject to this clinical trial. The main pathologies will be systemic autoimmune diseases, asthma or chronic skin diseases justifying prolonged oral corticotherapy.
* Time between first corticoids delivery and randomization \< 1 month
* Patient who gave his non-opposition
Note: Depending on their health condition, patient may receive one or more intravenous injections of methylprednisolone (until 3 injections), before the beginning of oral corticotherapy.
Exclusion criteria :
* Age \< 18 years or whose disability warrants a guardianship
* All patients for whom corticoids prescribed \<20 mg per 24 hours or for an expected period \<3 months
* Intramuscular or intravenous sequential corticoids delivery, without associated per os corticoids.
* Any corticotherapies other than prednisone, prednisolone or methylprednisolone.
* Any corticotherapies with alternating doses
* Intravenous or intramuscular injection corticotherapy
* Patient who received corticoids at a dose \>20 mg / day, during 3 last years
* Allergy, hypersensitivity or cons-indication to corticoids
* The existence of diabetes before corticotherapy, because pre-existing diabetes requires specific follow-up treatment, such as sugars restrictions
* Uncontrolled hypertension (SBP ≥ 180mHg or DBP ≥ 110mHg)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01420133
Study Brief:
Protocol Section:
NCT01420133